Phaseline

Targets › SHANK3

SHANK3 (SH3 and multiple ankyrin repeat domains protein 3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Other; next expected readout May 2027.

Major scaffold postsynaptic density protein which interacts with multiple proteins and complexes to orchestrate the dendritic spine and synapse formation, maturation and maintenance. Interconnects receptors of the postsynaptic membrane including NMDA-type and metabotropic glutamate receptors via complexes with GKAP/PSD-95 and HOMER, respectively, and the actin-based cytoskeleton. (UniProt, Q9BYB0)

Open in Phaseline: the race on SHANK3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Peking University First HospitalRB001
Gene therapy targeting SHANK3 deficiency
SHANK3Phase 1Phelan-McDermid SyndromeMay 2027
Jaguar Gene TherapyJAG201
Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9
SHANK3Phase 1SHANK3 HaploinsufficiencyJun 2028

Conditions

SHANK3 Haploinsufficiency (1) Phelan-McDermid Syndrome (1)

Modalities

other (2)

Companies

Jaguar Gene Therapy (1) Peking University First Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.